Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health Announces Second Quarter 2019 Operating Results
TYMLOS® U.S. net sales were $41.0 million in the second quarter of 201 9, an 81% growth over the second quarter of 2018. TYMLOS continued increasing its share of the U.S. anabolic osteoporosis market capturing an average of 35% total market share and 46% share in new patients in the second quarter
View HTML
Toggle Summary Radius Health Initiates Phase 3 wearABLe Study of Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at High Risk for Fracture
Abaloparatide-Patch patient assessment study results demonstrated high patient acceptability and self-administration accuracy over a 29-day period Levels of PINP, a biomarker for bone formation, after one month in patient assessment study were consistent with results in Phase 3 ACTIVE study of
View HTML
Toggle Summary Radius Health to Announce Second Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, August 7, 2019
WALTHAM, Mass. , July 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter 2019 financial results on Wednesday, August 7 th , 2019. The Company will host a conference call and live audio webcast at 4:30 p.m.
View HTML
Toggle Summary Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. , July 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted a new employee an option to purchase 65,000 shares of the Company’s common stock with a per
View HTML
Toggle Summary Radius Health to Present at Goldman Sachs 40th Annual Global Healthcare Conference
WALTHAM, Mass. , June 04, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona , Chief Financial Officer and Joe Kelly , Senior Vice President of Sales and Marketing, will present a corporate update at the Goldman Sachs 40th Annual Global Healthcare
View HTML
Toggle Summary Radius Health to Present at Bank of America Merrill Lynch Health Care Conference 2019
WALTHAM, Mass. , May 10, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona , Chief Financial Officer and Joe Kelly , Senior Vice President of Sales and Marketing, will present a corporate update at the Bank of America Merrill Lynch Health Care Conference
View HTML
Toggle Summary Radius Health Announces First Quarter 2019 Operating Results
TYMLOS® U.S. net sales were $29.8 million in the first quarter of 201 9 doubling over the first quarter of 2018. TYMLOS continued increasing its share in the U.S. anabolic osteoporosis market capturing an average of 30% total market share and 42% share in new patients in the first quarter of 2019.
View HTML
Toggle Summary Radius Health to Announce First Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, May 8, 2019
WALTHAM, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter 2019 financial results on Wednesday, May 8, 2019 . The Company will host a conference call and live audio webcast at 8:00 a.m.
View HTML
Toggle Summary Radius Health to Present Two Posters at AACE 2019 Annual Meeting
WALTHAM, Mass. , April 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it
View HTML
Toggle Summary Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies provide explanations for the net bone gain observed in the Phase 3 ACTIVE trial in abaloparatide-treated
View HTML